

# Direct Intercalation of Cisplatin into Zirconium Phosphate Nanoplatelets for Potential Cancer Nanotherapy

Agustín Díaz,<sup>a,b</sup> Millie L. González,<sup>c</sup> Riviam J. Pérez,<sup>a</sup> Amanda David,<sup>a,b</sup> Atashi Mukherjee,<sup>b</sup> Adriana Báez,<sup>c</sup> Abraham Clearfield<sup>b</sup> and Jorge L. Colón<sup>\*a</sup>

- a) Department of Chemistry, University of Puerto Rico, PO Box 23346, Río Piedras, PR 00931-3346, USA.  
b) Department of Chemistry, Texas A&M University, PO Box 30012, College Station, TX 77842-3012, USA.  
c) Departments of Pharmacology and Otolaryngology, School of Medicine, University of Puerto Rico, PO Box 365067, San Juan, PR 00936-5067, USA.

## Supporting Information:

**Page – S2:**

**Fig. S1:** Diffuse reflectance spectra of  $\alpha$ -ZrP and of the intercalation products of the reaction of ZrP and cisplatin at several cisplatin:ZrP molar ratios.

**Page – S3:**


**Fig. S2:**  $^{31}\text{P}$  MAS-NMR spectra of cisplatin intercalated ZrP at 5:1, 1:1, 1:5, 1:10, and 1:20 cisplatin:ZrP molar ratios.

**Page – S4:**


**Table S1:** Percentage of viable and early apoptotic MCF-7 cells analyzed by flow cytometry with annexin V-FITC/PI double staining after 48-h exposure to ZrP and cisplatin@ZrP(1:1)

**Page – S5:**

**Fig. S3:** Flow cytometric analysis of the cell cycle of untreated control MCF-7 cells at 24 hours (A), and 48 hours (C), ZrP (10  $\mu\text{M}$ ) treated cells after 24 hours (B) and 48 hours (D) of exposure




**Fig. S1.** Diffuse reflectance spectra of  $\alpha$ -ZrP and of the intercalation products of the reaction of ZrP and cisplatin at several cisplatin:ZrP molar ratios.



**Fig. S2:**  $^{31}\text{P}$  MAS-NMR spectra of cisplatin intercalated ZrP at 5:1, 1:1, 1:5, 1:10, and 1:20 cisplatin:ZrP molar ratios.

**Table S1:** Percentage of viable and early apoptotic MCF-7 cells analyzed by flow cytometry with annexin V-FITC/PI double staining after 48-h exposure to ZrP and cisplatin@ZrP(1:1)

Parameter	Percentage	
	Viable cells Annexin V (-) / PI (-)	Early apoptotic cells Annexin V (+) / PI (-)
Control	51.2	11.7
ZrP	44.4	17.2
cisplatin@ZrP (1:1 molar ratio)	32.6	30.5



**Fig. S3.** Flow cytometric analysis of the cell cycle of untreated control MCF-7 cells at 24 hours (A), and 48 hours (C). ZrP (10  $\mu$ M) treated cells after 24 hours (B) and 48 hours (D) of exposure.